Publicaciones en colaboración con investigadores/as de Université Catholique de Louvain (9)

2021

  1. A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net

    Journal of Inherited Metabolic Disease, Vol. 44, Núm. 5, pp. 1124-1135

  2. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)

    Leukemia

  3. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

  4. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

    Leukemia

2020

  1. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 395, Núm. 10218, pp. 132-141

2018

  1. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

    New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528

  2. Rituximab plus lenalidomide in advanced untreated follicular lymphoma

    New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946

1997

  1. Molecular delineation of the commonly deleted segment in mature B-cell lymphoid neoplasias with deletion of 7q

    Genes Chromosomes and Cancer, Vol. 18, Núm. 2, pp. 147-150

1996

  1. BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders

    Genes Chromosomes and Cancer, Vol. 15, Núm. 1, pp. 38-47